Molbio Diagnostics Limited (NSE: Molbio) Q1 FY27: Strong Momentum in Truenat Test-kit Volume

Molbio Diagnostics Limited (NSE: MOLBIO) announced its financial results for the quarter ended June 30, 2026, following its listing on August 17, 2026. The company reported a strong performance with total income at ₹411.48 crore against ₹100.47 crore in Q1 FY26. The earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹103.68 crore compared to a loss of ₹14.50 crore in the same quarter last year.

Key Financial Metrics

The EBITDA margin improved significantly to 25.20% from (14.43%) in Q1 FY26, reflecting the operating leverage on rising test-kit volumes. The profit after tax (PAT) stood at ₹52.74 crore compared to a loss of ₹23.94 crore in Q1 FY26, with a PAT margin of 12.82% against (23.83%) in the previous year.

Operational Highlights

The growth in total income was driven by the continued volume of Truenat test-kit consumption across the 12,500+ Truenat devices sold in 90+ countries. The company has meaningful capacity headroom, with device and test-kit utilisation at 42% and 58% respectively, positioning it for a volume-led scale-up without near-term incremental capex. The pipeline of 34 additional assays across 22 diseases remains on track, extending beyond infectious disease into oncology and other non-communicable areas.

The management emphasized disciplined execution, sustained R&D intensity, and improving cash flow quality as the international and acquired businesses scale. The company is deepening its presence across Africa, Southeast Asia, and entering Latin America, while progressing regulatory pathways in developed markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Molbio Diagnostics Limited

Molbio Diagnostics Limited. Here’s a quick read on where the business and the stock stand today.

Symbol MOLBIO not found in TradeAlone database.